Weekly Update

Neal Bhutiani, Yan Li, Qianqian Zheng, Harshul Pandit, Xiaoju Shi, Yujia Chen, Youxi Yu, Zachary R. Pulliam, Min Tan, and Robert C. G. Martin II


Citation: Bhutiani, N., Li, Y., Zheng, Q. et al. Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. Ann Surg Oncol 27, 4348–4359 (2020). 

Synopsis: Electrochemotherapy (ECT) with IRE and FOLFIRINOX resulted in increased tumor-cell apoptosis in mice models. In five patients, ECT with either FOLFIRINOX or gemcitabine was well tolerated and resulted in no dose-limiting toxicities.

Giacomo Montagna, Anita Mamtani, Andrea Knezevic, Edi Brogi, Andrea V. Barrio, and Monica Morrow


Citation: Montagna, G., Mamtani, A., Knezevic, A. et al. Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy. Ann Surg Oncol 27, 4515–4522 (2020). 

Synopsis: Here we evaluate how often node-positive patients avoid ALND with NAC and identify predictors of retrieval of ≥3 SLNs and ALND avoidance. ALND was spared in 41% of patients; this was associated with receptor status, grade, and LVI.

Listen to the ASO's new podcast, Speaking of SurgOnc®

Speaking of SurgOnc Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).

The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals. Once a month, Dr. Greene will interview authors and leading experts in surgical oncology.

Listen to the podcast here.

ASO – The Leading Resource in Surgical Oncology

Annals of Surgical OncologyAnnals of Surgical Oncology (ASO) hails 2019 as a year of growth and influence with a 13% increase in editorials, the addition of a two new editorial sections and the introduction of “ASO Author Reflections.” ASO also had more than 1 million article downloads, a demonstration of the quality and relevance of the research published. Read more about ASO.

ASO is the journal of choice of surgical oncologists and cancer multidisciplinary teams worldwide regarding surgical oncology research and education, and benefits surgeons, oncologists, hematologists, radiologists, general practitioners, pathologists, researchers, academicians, and other clinical professionals interested in all aspects of the surgical treatment of cancer. ASO strives to improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.

Join the conversation! Follow the journal on Twitter and Facebook. Help to expand the reach of the journal to support the research and practice needs of surgical oncologists and their patients.

Scroll to Top